The use of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has now proven itself in its first phase 3 clinical trial.
Crucially, the scientists say, the benefits of the drug came without the cost of hallucinations, a side effect which may aggravate stress.
This comes after the FDA also recently allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD.
Analytical Cannabis' sister publication, Technology Networks, explores the benefits of psychedelic-assisted therapy.
A new technology developed by researchers at the University of California Davis promises to fast-track the development of compounds that could exploit psychedelics’ therapeutic action without hallucinogenic side effects.
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.
N,N-dimethyltryptamine (DMT) is a psychedelic compound under investigation for a range of therapeutic uses. One avenue of research is being pursued by Algernon Pharmaceuticals, who are investigating whether sub-hallucinogenic DMT doses could help to protect and repair the brain in the hours after a stroke.